Evidence mapPaperPMID 40434692Full record

ReviewMolecular biology reports2025

An overview on cardiac regeneration revolution: exploring the promise of stem cell therapies.

Parisa Noorabadi, Venus Shahabi Rabori, Sara Jamali, Negar Jafari, Mohammadreza Saberiyan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Parisa Noorabadi *Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0000-0002-3688-6443
Venus Shahabi Rabori *Department of Cardiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0000-0001-5150-6018
Sara JamaliDepartment of Medical Genetics, School of Medical Sciences, Faculty of Medicine, Hormozgan University of Medical Sciences, P.O.Box: 7919693116, Bandar Abbas, Iran.ORCID https://orcid.org/0000-0002-6806-6327
Negar JafariDepartment of Cardiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. jnegar94@gmail.com.ORCID https://orcid.org/0000-0002-6249-2587
Mohammadreza SaberiyanDepartment of Medical Genetics, School of Medical Sciences, Faculty of Medicine, Hormozgan University of Medical Sciences, P.O.Box: 7919693116, Bandar Abbas, Iran. saberiyanmr@gmail.com.ORCID https://orcid.org/0000-0001-6343-8518

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of global mortality, with myocardial infarction (MI) and subsequent heart failure (HF) posing significant clinical challenges. Despite advancements in pharmacological and surgical interventions, the limited regenerative capacity of the adult human heart necessitates innovative therapeutic strategies. Stem cell-based therapies have emerged as a promising approach to cardiac regeneration, aiming to restore damaged myocardial tissue through cell replacement and paracrine-mediated repair mechanisms. This review provides a comprehensive overview of the current landscape of stem cell therapies for cardiac regeneration, focusing on the molecular mechanisms, cell types, delivery techniques, and recent clinical advancements. We highlight the roles of key signaling pathways, including NOTCH, PI3K/Akt, Wnt/β-catenin, Hippo/YAP, and MAPK, in regulating cardiomyocyte proliferation, angiogenesis, fibrosis, and inflammation. Additionally, we discuss the therapeutic potential of various stem cell types, such as mesenchymal stem cells (MSCs), cardiac progenitor cells (CPCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs), in promoting cardiac repair. Despite promising preclinical results, challenges such as low cell retention, immune rejection, and inconsistent clinical outcomes persist. Recent advancements in genetic engineering, and innovative delivery methods, including transendocardial and intracoronary injections, offer new avenues for enhancing therapeutic efficacy. This review underscores the need for further research to optimize stem cell-based therapies, improve clinical trial design, and translate these innovative approaches into effective treatments for heart disease. By addressing these challenges, stem cell therapy holds the potential to revolutionize cardiac regeneration and improve outcomes for patients with ischemic heart disease and heart failure.

Indexed as

HeartRegenerationStem Cell TransplantationAnimalsCardiovascular DiseasesHeart FailureHumansMyocardial InfarctionMyocytes, CardiacRegenerative MedicineSignal TransductionCardiac diseasesCardiac regenerationCell therapyStem cell

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.